TY - JOUR
T1 - Calcium plus linoleic acid therapy for pregnancy-induced hypertension
AU - Herrera, J. A.
AU - Shahabuddin, A. K.M.
AU - Ersheng, G.
AU - Wei, Yuan
AU - Garcia, R. G.
AU - López-Jaramillo, P.
PY - 2005/12
Y1 - 2005/12
N2 - Objective: To determine the effect of dietary supplementation of calcium plus conjugated linoleic acid (calcium-CLA) in reducing the incidence of vascular endothelial dysfunction in pregnant women at high risk of developing pregnancy-induced hypertension (PIH). Patients and methods: This randomized, double-blind, placebo-controlled trial conducted at 4 outpatient clinics in 2 developing countries recruited 48 healthy primigravidas younger than 19 years or older than 35 years who had a family history of pre-eclampsia and diastolic notch. Twenty-four participants received daily elemental calcium (600 mg) plus CLA (450 mg) and 24 received placebo from week 18 to 22 of pregnancy until delivery. Results: Calcium-CLA supplementation reduced significantly the incidence of PIH (2 cases [8%] in the study group vs. 10 cases [42%] in the placebo group; relative risk, 0.20; 95% confidence interval, 0.05-0.82; P = .01). Endothelial dysfunction was also significantly reduced after calcium-CLA supplementation (in 18 women [75%] vs. 4 women [17%]; P < .001), compared with the placebo group (in 15 [63%] vs. 9 women [38%]; P = .08). Conclusion: In pregnant women at high risk for PIH, calcium-CLA supplementation decreases the incidence of PIH and improves endothelial function.
AB - Objective: To determine the effect of dietary supplementation of calcium plus conjugated linoleic acid (calcium-CLA) in reducing the incidence of vascular endothelial dysfunction in pregnant women at high risk of developing pregnancy-induced hypertension (PIH). Patients and methods: This randomized, double-blind, placebo-controlled trial conducted at 4 outpatient clinics in 2 developing countries recruited 48 healthy primigravidas younger than 19 years or older than 35 years who had a family history of pre-eclampsia and diastolic notch. Twenty-four participants received daily elemental calcium (600 mg) plus CLA (450 mg) and 24 received placebo from week 18 to 22 of pregnancy until delivery. Results: Calcium-CLA supplementation reduced significantly the incidence of PIH (2 cases [8%] in the study group vs. 10 cases [42%] in the placebo group; relative risk, 0.20; 95% confidence interval, 0.05-0.82; P = .01). Endothelial dysfunction was also significantly reduced after calcium-CLA supplementation (in 18 women [75%] vs. 4 women [17%]; P < .001), compared with the placebo group (in 15 [63%] vs. 9 women [38%]; P = .08). Conclusion: In pregnant women at high risk for PIH, calcium-CLA supplementation decreases the incidence of PIH and improves endothelial function.
KW - Calcium
KW - Conjugated linoleic acid
KW - Pre-eclampsia
KW - Pregnancy-induced hypertension
KW - Prevention
KW - Vascular endothelial function
UR - http://www.scopus.com/inward/record.url?scp=27744587722&partnerID=8YFLogxK
U2 - 10.1016/j.ijgo.2005.08.018
DO - 10.1016/j.ijgo.2005.08.018
M3 - Artículo Científico
C2 - 16243339
AN - SCOPUS:27744587722
SN - 0020-7292
VL - 91
SP - 221
EP - 227
JO - International Journal of Gynecology and Obstetrics
JF - International Journal of Gynecology and Obstetrics
IS - 3
ER -